Huan Xie

Dr. Huan Xie

Texas Southern University
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Journal of Environmental Pathology, Toxicology and Oncology
Verified
Journal Article
Closed access
PDF file
Ritu GuptaRitu Gupta
Ritu Gupta
Huan XieHuan Xie
Huan Xie
At nanoscale, man-made materials may show unique properties that differ from bulk and dissolved counterparts. The unique properties of engineered nanomaterials not only impart critical advantages but also confer toxicity because of their unwanted interactions with different biological compartments and cellular processes. In this review, we discuss various entry routes of nanomaterials in the human body, their applications in daily life, and the mechanisms underlying their toxicity. We further explore the passage of nanomaterials into air, water, and soil ecosystems, resulting in diverse environmental impacts. Briefly, we probe the available strategies for risk assessment and risk management to assist in reducing the occupational risks of potentially hazardous engineered nanomaterials including the control banding (CB) approach. Moreover, we substantiate the need for uniform guidelines for systematic analysis of nanomaterial toxicity, in silico toxicological investigations, and obligation to ensure the safe disposal of nanowaste to reduce or eliminate untoward environmental and health impacts. At the end, we scrutinize global regulatory trends, hurdles, and efforts to develop better regulatory sciences in the field of nanomedicines.

1 May 2012 in International Journal of Nanomedicine
Verified
Journal Article
Open access
Huan XieHuan Xie
Huan Xie
BGBeth Goins
Beth Goins
ABAnde Bao
Ande Bao
ZWZheng Jim Wang
Zheng Jim Wang
WPWilliam T Phillips
William T Phillips
Peer reviewed article authored by (Xie H, Goins B, Bao A, Wang ZJ, Phillips WT). Read article or submit your manuscript for publishing.

15 June 2021 in WIREs Nanomedicine and Nanobiotechnology
Verified
Journal Article
Closed access
PDF file
Ritu GuptaRitu Gupta
Ritu Gupta
YCYuan Chen
Yuan Chen
Huan XieHuan Xie
Huan Xie

18 August 2022 in WIREs Nanomedicine and Nanobiotechnology
Verified
Journal Article
Closed access
MSMahua Sarkar
Mahua Sarkar
YWYang Wang
Yang Wang
OEOscar Ekpenyong
Oscar Ekpenyong
Dong LiangDong Liang
Dong Liang
Huan XieHuan Xie
Huan Xie

28 August 2014 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
SLSu Liang
Su Liang
BSBeatriz Sanchez‐Espiridion
Beatriz Sanchez‐Espiridion
Huan XieHuan Xie
Huan Xie
JMJing Ma
Jing Ma
XWXifeng Wu
Xifeng Wu
Dong LiangDong Liang
Dong Liang

29 November 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Ritu GuptaRitu Gupta
Ritu Gupta
YCYuan Chen
Yuan Chen
MSMahua Sarkar
Mahua Sarkar
Huan XieHuan Xie
Huan Xie
In vitro drug release testing is an important quality control tool for formulation development. However, the literature has evidence that poly-lactide-co-glycolide (PLGA)-based formulations show a slower in vitro drug release than a real in vivo drug release. Much longer in vitro drug release profiles may not be reflective of real in vivo performances and may significantly affect the timeline for a formulation development. The objective of this study was to develop a surfactant mediated accelerated in vitro drug release method for the PLGA nanoparticles (NPs) of a novel chemotherapeutic agent AC1LPSZG, a model drug with a poor solubility. The Sotax USP apparatus 4 was used to test in vitro drug release in a phosphate buffer with a pH value of 6.8. The sink conditions were improved using surfactants in the order of sodium lauryl sulfate (SLS) < Tween 80 < cetyltrimethylammonium bromide (CTAB). The dissolution efficiency (DE) and area under the dissolution curve (AUC) were increased three-fold when increasing the CTAB concentration in the phosphate buffer (pH 6.8). Similar Weibull release kinetics and good linear correlations (R2~0.99) indicated a good correlation between the real-time in vitro release profile in the phosphate buffer (pH 6.8) and accelerated release profiles in the optimized medium. This newly developed accelerated and discriminatory in vitro test can be used as a quality control tool to identify critical formulation and process parameters to ensure a batch-to-batch uniformity. It may also serve as a surrogate for bioequivalence studies if a predictive in vitro in vivo correlation (IVIVC) is obtained. The results of this study are limited to AC1LPSZG NPs, but a similar consideration can be extended to other PLGA-based NPs of drugs with similar properties and solubility profiles.